BARDA Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

The latest BARDA Broad Agency Announcement (BAA) is amendment 14 posted on March 9, 2020.

Note: COVID-19 response related Areas of Interest includes:

AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
AOI 8.3 COVID-19 Vaccine
AOI 9.2 COVID-19 Therapeutics
AOI 9.3 Immunomodulators or therapeutics targeting lung repair
AOI 9.5 Pre-exposure and post-exposure prophylaxis
AOI 10 Respiratory protective devices
AOI 11 Ventilators
AOI 17 Advanced Manufacturing Technologies

Sponsor or Type
Deadline
4/30/20

Subscribe to the University of Arizona Impact in Action newsletter to receive featured stories and event info to connect you with UArizona's research, innovation, entrepreneurial ventures, and societal impacts.

Subscribe now